Brand dynamics

Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health

Lizhu Pharmaceutical and NeuroSense Therapeutics have reached an exclusive license agreement for Greater China for NS-041, a highly selective KCNQ2/3 activator.

Published Time:

2024-07-18

 

Recently ,Lizhu Pharmaceutical Group Co., Ltd.'s wholly-owned subsidiary, Lizhu Pharmaceutical Factory (hereinafter referred to as “Lizhu Pharmaceutical”), and Nuoxin Pharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as “Nuoxin Pharmaceuticals”)—an international biotechnology company focused on developing innovative therapies for neurological and psychiatric diseases, have reached an exclusive license agreement for Greater China for NS-041, a small molecule candidate drug owned by Nuoxin Pharmaceuticals. Both parties will cooperate closely on this basis to accelerate the listing process of NS-041.

 

According to the agreement, Lizhu Pharmaceutical will exclusively obtain all rights and interests of NS-041 in Greater China. Lizhu Pharmaceutical will work closely with Nuoxin Pharmaceuticals to promote the subsequent development of NS-041 in Greater China, while Nuoxin Pharmaceuticals will continue to lead the development and commercialization of NS-041 in other global regions.

 

NS-041 is a highly selective KCNQ2/3 activator, targeting the treatment of neurological and psychiatric diseases such as epilepsy and depression. NS-041 has shown good and differentiated preclinical efficacy and safety data, and has the potential to be best-in-class. A randomized, double-blind, placebo-controlled Phase I clinical study has been initiated in China.

 

Potassium channels KCNQ2/3 is considered one of the important targets for the development of next-generation antiepileptic drugs. Its novel mechanism of action is expected to fill the gaps in current treatment methods. In addition, the potential indications of this target can be expanded to various emotional disorders, in order to make up for the unmet clinical needs of existing drugs, such as slow onset and insufficient efficacy. Currently, global candidate drugs with the same target are in the clinical research stage and have obtained positive data on epilepsy and major depressive disorder.

 

Mr. Tang Yanggang, Executive Director and President of Lizhu Pharmaceutical, said: “This cooperation with Nuoxin Pharmaceuticals will further expand Lizhu Pharmaceutical’s pipeline in the field of psychiatry and neurology. We are optimistic about the future market potential of NS-041, and both parties will give full play to their respective advantages to accelerate the listing of NS-041.”

 

Dr. Shen Huajiong, Founder and CEO of Nuoxin Pharmaceuticals, said: “We are very pleased to reach this agreement with Lizhu Pharmaceutical on NS-041. This is a recognition of Nuoxin Pharmaceuticals’ R&D capabilities and demonstrates our confidence in Lizhu Pharmaceutical’s future commercialization capabilities. As a new mechanism of action innovative drug, NS-041 is expected to address unmet needs in various central nervous system diseases, with global competitiveness and huge commercial potential. Both parties will work closely together in subsequent clinical development to jointly advance the development of NS-041.”

 

About Lizhu Pharmaceutical: Lizhu Pharmaceutical Group Co., Ltd. ( 000513.SZ,01513.HK) was founded in 1985, with a registered capital of 926 million yuan. It is a comprehensive pharmaceutical group company integrating pharmaceutical R&D, production, and sales, with nearly 9,000 employees. Lizhu is committed to the R&D, production, and sales of raw materials, small molecule drugs, macromolecular drugs, and diagnostic reagents. Its key therapeutic areas cover anti-tumor, assisted reproduction, digestive tract, anti-infection, and mental/neurological fields.

 

About Nuoxin Pharmaceuticals: Nuoxin Pharmaceuticals is a clinical-stage international biotechnology company focused on developing innovative therapies for neurological and psychiatric diseases. The company has R&D centers in Shanghai, China and Boston, USA, and has a world-class new drug R&D team in the field of neurological and psychiatric diseases, with senior leaders from academia and industry joining the board of directors and scientific advisory committee. The company has established a rich and leading CNS pipeline, and its core projects are undergoing clinical development and have best-in-class potential.

This article is from: Lizhu Pharmaceutical